Submitting OIG:
Report Description:
Drug diversion, counterfeiting, and the importation of unapproved drugs may result in potentially dangerous drugs entering the drug supply chain, posing a threat to public health and safety. To enhance drug supply chain security, the Drug Supply Chain Security Act (DSCSA) requires trading partners in the drug supply chain to create a record of each drug product transaction. FDA can then use such tracing records to investigate suspect and illegitimate drug products and potential diversion.
Date Issued:
Tuesday, September 12, 2017
Agency Reviewed / Investigated:
Submitting OIG-Specific Report Number:
OEI-05-14-00640
Component, if applicable:
Centers for Medicare & Medicaid Services
Location(s):
Agency-Wide
Type of Report:
Inspection / Evaluation
Questioned Costs:
$0
Funds for Better Use:
$0
Number of Recommendations:
3
View Document:
Attachment | Size |
---|---|
oei-05-14-00640.pdf | 2.23 MB |
Additional Details Link: